OncoMatch/Colorectal Cancer (CRC)/MSH6
Colorectal Cancer (CRC)MSH6 Clinical Trials
MSH6 loss by IHC defines dMMR status and MSI-H eligibility for checkpoint immunotherapy in colorectal cancer. MSH6 deficiency can result from germline Lynch syndrome mutations or somatic inactivation. Trials for dMMR/MSI-H CRC broadly enroll MSH6-deficient patients, who benefit from pembrolizumab, nivolumab, and combination PD-1/CTLA-4 inhibition.
Top recruiting MSH6 Colorectal Cancer (CRC) trials
Ranked by phase and US site count. See all 35 trials matched to your profile →
Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC
Sun Yat-sen University
mFOLFOX6 + Bevacizumab + PD-1 Monoclonal Antibody Vs. mFOLFOX6 in Locally Advanced pMMR/MSS CRC
Jun Huang
Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients
Sun Yat-sen University
Node-sparing Short-Course Radiation Combined With CAPOX and Tislelizumab for MSS Rectal Cancer
Sir Run Run Shaw Hospital
PACE: PD-1 Antibody For dMMR/MSI-H Stage III Colorectal Cancer
Sun Yat-sen University
Node-Sparing Short-Course Radiotherapy Sequential Chemotherapy and PD-1 Inhibitor for Mid/Low pMMR/MSS Rectal Cancer (MODIFI-RC-II)
Sixth Affiliated Hospital, Sun Yat-sen University
Browse other molecular targets with active Colorectal Cancer (CRC) trials.